Oncologic emergency — fever ≥38.3°C in a patient with ANC <500 — requires immediate empiric broad-spectrum antibiotics.
Try two board-style Febrile Neutropenia / Neutropenic Fever questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1HematologyMedium
A patient on chemotherapy has a temperature of 38.6°C and an absolute neutrophil count of 300/mm3. Which of the following is the most appropriate initial management?
- AEmpiric intravenous vancomycin
- BEmpiric antipseudomonal beta-lactam
- CGranulocyte colony-stimulating factor
- DHold antibiotics until cultures result
Reveal answer & full explanation
Correct answer: B — Empiric antipseudomonal beta-lactam
- AEmpiric intravenous vancomycin
- BEmpiric antipseudomonal beta-lactam✓
- CGranulocyte colony-stimulating factor
- DHold antibiotics until cultures result
Why Empiric antipseudomonal beta-lactam is correct
- Febrile neutropenia is an oncologic emergency demanding immediate broad-spectrum empiric coverage.
- Cefepime, piperacillin-tazobactam, or meropenem provide the required antipseudomonal activity.
- Blood cultures are drawn but must not delay the first antibiotic dose.
Why the others are wrong
- Hold antibiotics until cultures result — any delay sharply increases mortality in neutropenic fever; this is the diagnostic-delay trap.
- Empiric intravenous vancomycin — vancomycin covers only gram-positive organisms and is not part of standard initial therapy; it is added to the antipseudomonal beta-lactam only for hemodynamic instability, suspected catheter-related or skin and soft-tissue infection, pneumonia, or known MRSA colonization, and starting it as the initial agent leaves Pseudomonas and enteric gram-negatives uncovered; this is the broad-spectrum-sounding trap.
- Granulocyte colony-stimulating factor — G-CSF is used as prophylaxis with high-risk chemotherapy regimens and is not routinely recommended to treat established febrile neutropenia; it takes days to raise the neutrophil count and never substitutes for immediate empiric antibiotics; this is the fix-the-number trap.
Question 2HematologyMedium
A 58-year-old woman with diffuse large B-cell lymphoma presents 10 days after her first cycle of high-dose cytotoxic chemotherapy with a single temperature of 38.5 C (101.3 F) and mild fatigue. She has no localizing symptoms, and her vital signs are otherwise stable. Which of the following laboratory findings is most likely to be present?
- AAbsolute neutrophil count below 500 cells/microL
- BWhite blood cell count of 18,000 cells/microL
- CAbsolute lymphocyte count below 500 cells/microL
- DPlatelet count below 20,000 cells/microL
Reveal answer & full explanation
Correct answer: A — Absolute neutrophil count below 500 cells/microL
- AAbsolute neutrophil count below 500 cells/microL✓
- BWhite blood cell count of 18,000 cells/microL
- CAbsolute lymphocyte count below 500 cells/microL
- DPlatelet count below 20,000 cells/microL
Why Absolute neutrophil count below 500 cells/microL is correct
- This patient has febrile neutropenia, and the confirmatory laboratory finding is an absolute neutrophil count below 500 cells/microL (or below 1,000 and expected to fall below 500) together with a single temperature of at least 38.3 C or a sustained 38.0 C.
- Cytotoxic chemotherapy kills dividing marrow progenitors, and the neutrophil nadir occurs roughly 7 to 14 days after treatment, exactly the window this patient is in, making profound neutropenia the expected and defining finding.
Why the others are wrong
- White blood cell count of 18,000 cells/microL — describes a neutrophilic leukocytosis, the opposite of neutropenia, and would point toward an ordinary bacterial infection with intact marrow rather than chemotherapy-induced myelosuppression.
- Absolute lymphocyte count below 500 cells/microL — reflects lymphopenia, which can accompany chemotherapy but is not the criterion that defines this syndrome; the diagnosis hinges specifically on neutrophils.
- Platelet count below 20,000 cells/microL — indicates severe thrombocytopenia — also common after chemotherapy — but it predicts bleeding risk, not the infection risk that febrile neutropenia captures, and it is not part of the diagnostic definition.
The depth and duration of the neutrophil nadir determine infection risk, so the ANC is the number that both confirms the diagnosis and drives urgent empiric antibiotics.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Febrile Neutropenia / Neutropenic Fever outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Intensive chemotherapy regimens (AML induction, lymphoma R-CHOP-like, stem cell transplant conditioning)
- Prolonged or severe neutropenia (ANC <100 for >7 days)
- Prior episodes of febrile neutropenia
- Age >65, poor performance status
- Mucositis, indwelling central venous catheter
- Comorbidities — diabetes, CKD, COPD, hepatic dysfunction
Pathophysiology
Chemotherapy-induced neutropenia impairs the primary defense against bacterial and fungal pathogens. Loss of mucosal barrier integrity (mucositis) and presence of indwelling devices facilitate translocation of gut flora and skin organisms into the bloodstream. Without neutrophils, infection can progress rapidly to sepsis and septic shock; the classic inflammatory response is blunted, and fever may be the ONLY sign of serious infection.
Clinical presentation
Symptoms
- Fever may be the ONLY symptom — physical findings often blunted by neutropenia
- Rigors or chills
- Localized symptoms (cough, dysuria, abdominal pain, headache, line site pain) often subtle
- Mucositis, perirectal pain
- Hypotension, tachycardia, altered mental status if progressing to septic shock
Signs / physical exam
- Fever (defined above)
- Often LACK of classic findings — pus, abscess formation may not occur without neutrophils
- Careful exam: oropharynx, perianal area, indwelling line/port sites, skin/nails, lungs, abdomen
- Hemodynamic compromise — hypotension, tachycardia
- Erythema/induration at IV/catheter sites
Classic findings
Cancer patient 7-14 days after chemotherapy with isolated fever and no other localizing signs — start empiric antibiotics WITHIN 60 MINUTES of presentation.
Differential diagnosis
- Drug fever — Pattern of fevers with drug administration; eosinophilia; no infectious source — diagnosis of exclusion
- Transfusion reaction — Temporal relationship to blood product; rigors, hypotension, hemolysis labs
- Tumor fever — Lymphoma, leukemia, renal cell carcinoma can produce paraneoplastic fever; pattern of cyclical fevers; diagnosis of exclusion
- Engraftment syndrome / cytokine release syndrome — Peri-engraftment in HSCT or post CAR-T; rash, hypoxia, weight gain
- Venous thromboembolism — Can present with fever; cancer patients at high risk
- Adrenal insufficiency — After prolonged glucocorticoid courses; hypotension, hyponatremia
Diagnostic workup
Diagnostic criteria
Diagnosis is clinical: ANC <500 (or expected fall <500 in 48 h) + fever as defined. Risk stratification by MASCC (Multinational Association for Supportive Care in Cancer) score — score ≥21 indicates low risk and potential for outpatient oral therapy in select patients.
Labs
- CBC with differential — confirm ANC <500
- Blood cultures — ≥2 sets (one from peripheral vein and one from each lumen of indwelling central line)
- BMP, liver enzymes, lactate
- Urinalysis and urine culture
- Other site-specific cultures (sputum, stool, wound, CSF) based on symptoms
- Procalcitonin (variable utility)
- Respiratory viral PCR panel in respiratory symptoms or seasonal context
Imaging
- Chest X-ray (sensitivity reduced without neutrophils — consider CT chest in high-risk or persistent fevers)
- Site-specific imaging — abdominal CT for abdominal pain (typhlitis), sinus CT, brain MRI as indicated
Treatment
First-line
- EMPIRIC IV broad-spectrum antibiotics WITHIN 60 MINUTES of presentation — DO NOT wait for cultures
- Anti-pseudomonal beta-lactam monotherapy (high-risk patients): cefepime, piperacillin-tazobactam, meropenem, or imipenem-cilastatin
- Add vancomycin (or linezolid, daptomycin) if: hemodynamic instability, suspected catheter-related infection, skin/soft tissue infection, pneumonia with severe sepsis, mucositis with prior fluoroquinolone prophylaxis, or known MRSA colonization
- Continue antibiotics until ANC >500 and afebrile ≥48 hours, OR until completion of standard course if specific pathogen/site identified
Low-risk febrile neutropenia (MASCC ≥21, anticipated short neutropenia, clinically stable, no comorbidities, able to take PO, social support)
- Outpatient oral antibiotics — ciprofloxacin PLUS amoxicillin-clavulanate (or moxifloxacin alone)
- Close follow-up within 24-48 h
- Inpatient admission if any deterioration
High-risk febrile neutropenia (MASCC <21, AML/HSCT, prolonged neutropenia, hemodynamically unstable, comorbidities)
- Hospital admission, IV antibiotics
- Cefepime or piperacillin-tazobactam or carbapenem
- Add vancomycin if indicated (see above)
- G-CSF support (filgrastim, pegfilgrastim) for prolonged or severe neutropenia per ASCO guidelines
Persistent fever ≥4-7 days on broad-spectrum antibiotics
- Empiric antifungal coverage — echinocandin (caspofungin, micafungin, anidulafungin), liposomal amphotericin B, or voriconazole
- CT chest, sinus imaging, fungal markers (galactomannan, beta-D-glucan)
- Reassess for occult source — abscess, line infection (consider line removal), C. difficile, viral reactivation (CMV, HSV)
Septic shock
- ICU admission
- Broaden coverage to include MRSA, Pseudomonas, and consider empiric antifungal early
- Fluid resuscitation, vasopressors, source control
- Hydrocortisone for refractory shock
Second-line / adjunct
- Granulocyte colony-stimulating factors (filgrastim, pegfilgrastim) — primary prophylaxis when chemotherapy regimen has FN risk >20%; secondary prophylaxis after prior FN episode
- Fluoroquinolone prophylaxis (levofloxacin, ciprofloxacin) during prolonged severe neutropenia (controversial — resistance concerns)
- Posaconazole prophylaxis for AML induction/consolidation and high-risk HSCT to prevent invasive aspergillosis
Complications
- Septic shock and multi-organ failure
- Bacteremia, fungemia
- Invasive fungal infections (Candida, Aspergillus)
- Clostridioides difficile colitis
- Neutropenic enterocolitis (typhlitis) — Bacteroides, Clostridium, Pseudomonas; cecal pain, perforation risk
- Catheter-related bloodstream infection
- Treatment delays in cancer therapy from infection
- Mortality 5-50% depending on risk strata and source
PANCE pearls
- Door-to-antibiotic time <60 minutes is the single most important quality metric — every hour delay increases mortality.
- ABSENCE of pus or local inflammation does NOT exclude serious infection in neutropenic patients — neutrophils make pus.
- MASCC score ≥21 identifies low-risk patients who may be candidates for oral outpatient therapy (ciprofloxacin + amoxicillin-clavulanate) with close follow-up.
- Always add vancomycin in hemodynamically unstable patients, suspected catheter infection, or mucositis with fluoroquinolone prophylaxis — but de-escalate when no gram-positive pathogen identified at 48-72 h.
- Persistent fever ≥4-7 days on broad-spectrum antibiotics → add empiric antifungal coverage (echinocandin or liposomal amphotericin).
- Pegfilgrastim is given as a single dose ≥24 hours after chemotherapy completion; do NOT give within 14 days before next chemotherapy cycle.
- Typhlitis (neutropenic enterocolitis) classically presents with RLQ pain, fever, diarrhea in a neutropenic patient — treat with broad-spectrum antibiotics, bowel rest, and surgical consultation.
References
- IDSA 2010 (updated) — Freifeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by IDSA. Clin Infect Dis 2011; 52:e56-93.
- ASCO/IDSA 2018 — Taplitz RA et al. Outpatient management of fever and neutropenia in adults treated for malignancy: ASCO/IDSA Clinical Practice Guideline Update. J Clin Oncol 2018.
- MASCC Score — Klastersky J et al. The Multinational Association for Supportive Care in Cancer risk index. J Clin Oncol 2000; 18:3038-3051.
- NCCN — NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections.